Pfizer has been granted FDA approval for Xeljanz (tofacitinib) 5 mg twice daily for the treatment of adults with moderate to severe active rheumatoid arthritis who had an inadequate response or is intolerant to methotrexate (MTX). FDA has asked for additional data to assess the risk and benefit of 10 mg twice daily dose. We do not see the advantage of oral delivery (twice daily) as important, when injectable drugs are administered once fortnightly (subcutaneous) or much less frequent than tofacitinib. Besides no differentiation from a clinical perspective over existing drugs which are well entrenched, we forecast a slow ramp up driven by penetration in, (i) an inadequate response or intolerant to MTX, biologic-naïve pts, and (ii) in non-responders to anti-TNF alpha therapy. Pfizer is also planning to discuss with FDA for the role of tofacitinib as first-line treatment option based on ORAL-Start two-year study which demonstrated superior efficacy (inhibiting structural damage) versus methotrexate with similar tolerability issues. Taken together, we project ww peak sales of $1.2b by 2017 for Xeljanz
PFIZER, Xeljanz (tofacitinib) approved for RA, but we see limited potential
Date:
2015-07
MORE PUBLICATIONS
Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
- Mayo Clinic – Strategic SWOT Analysis Review
- Global Energy Drink Market Will Grow At A CAGR Of Approximately 8.6%
- Global Disposable Diapers Market Analysis
- Sprint Corporation (S) – Financial and Strategic SWOT Analysis Review
- AMC Entertainment, Inc. – Strategic SWOT Analysis Review
- NVIDIA Corporation (NVDA) – Financial and Strategic SWOT Analysis Review
- 2017年全球智能温室系统(Smart Greenhouse System)市场及投资分析报告(优惠版)
- Global In Vitro Diagnostics (IVD) Market Analysis By Technology
- Global Blockchain Technology Market Worth $ 5.6 Billion by 2022
- 2016 Special Report on Metamaterial Market